Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Cellsource Co., Ltd. (4880:JPX), powered by AI.
Cellsource Co., Ltd. is currently trading at ¥394. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Cellsource Co., Ltd. on Alpha Lenz.
View Cellsource Co., Ltd.'s valuation metrics on Alpha Lenz.
“Cellsource Co., Ltd.'s ROE is 0.2%. Explore profitability and growth together.”
Ask for details →Cellsource Co., Ltd. is a biotechnology company that focuses on the development and commercialization of regenerative medicine products. Specializing in cell-based therapies, Cellsource aims to leverage cutting-edge technology and scientific expertise to contribute to advancements in medical treatments for various ailments and conditions. The company's primary objective is to harness the potential of cell therapy to improve patient outcomes and quality of life. Operating within the dynamic and fast-evolving biotechnology sector, Cellsource conducts research and development activities to pioneer innovative medical solutions. The firm plays an integral role in the biotech industry, collaborating with research institutions, healthcare providers, and other stakeholders to bring innovative therapies to market. As a key player in the regenerative medicine landscape, Cellsource is committed to advancing the frontiers of medical technology and contributing to the future of personalized medicine through its research and product offerings.
“Cellsource Co., Ltd.'s ROE is 0.2%. Explore profitability and growth together.”
Ask for details →Cellsource Co., Ltd. (ticker: 4880) is a company listed on JPX in the Healthcare sector (Biotechnology). It has approximately 151 employees.
The current price is 394 with a P/E ratio of -x and P/B of -x.
ROE is 0.18% and operating margin is 4.49%. Annual revenue is $3.7B.